VEGF isoforms and their use as anti-angiogenic,...

Details VEGF isoforms and their use as anti-angiogenic,... VEGF isoforms and their use as anti-angiogenic,...

2002-07-12

2010-10-26

Spector, Lorraine (Department: 1647)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Hormone or other secreted growth regulatory factor,...

C435S069100, C435S069700, C530S399000

Reexamination Certificate

active

07820178

ABSTRACT:
An isolated VEGF polypeptide having anti-angiogenic activity, said polypeptide including the amino acid sequence of SEQ. ID NO. 1, or variants thereof.

REFERENCES:
patent: 6911331 (2005-06-01), Famodu et al.
patent: 7094953 (2006-08-01), Wright et al.
patent: 9816551 (1998-04-01), None
patent: 9940197 (1999-08-01), None
patent: 1999050403 (1999-10-01), None
patent: 0013702 (2000-03-01), None
patent: 2000062063 (2000-10-01), None
patent: 0153345 (2001-07-01), None
patent: 0156645 (2001-08-01), None
L.A. Cogburn et al., Journal of Nutrition, 119:1213-1222, 1989.
K. Das et al., Differential expression of vascular endothelial growth factor165b in transitional cell carcinoma of the bladder, Urologic oncology (United States) Jul.-Aug. 2007, 25 (4) p. 317-21.
Locus Q00668, D.W. Brown et al., Nov. 1, 1997, accessed Sep. 19, 2008. Attached as appendix to Office Action.
Locus A85025, The European Union Arabidopsis Genome Sequencing Consortium, the Cold Spring Harbor, Washington University in St. Louis and PE Biosystems Arabidopsis Sequencing Consortium, Feb. 16, 2001, accessed Sep. 19, 2008. Attached as appendix to Office Action.
Locus B70592, R. Cole et al., Jul. 17, 1998, accessed Sep. 19, 2008. Attached as appendix to Office Action.
Locus JC5387,T. Toki et al., Mar. 5, 1998, accessed Sep. 19, 2008. Attached as appendix to Office Action.
Poltorak, et al., “The VEGF Splice Variants: Properties, Receptors, and Usage for the Treatment of Ischemic Diseases”, Hertz, vol. 25 (2), pp. 126-129, (2000).
Tischer, et al., “The Human Gene for Vascular Endothelial Growth Factor”, Journal of Biological Chemistry, vol. 266 (18), pp. 11947-11954, (1991).
Wellman, et al., “Specific Reverse Transcription-PCR Quantification of Vascular Endothelial Growth Factor (VEGF) Splice Variants by LightCycler Technology”, Clinical Chemistry, vol. 47 (4), pp. 654-660 (2001).
De Laurenzi V, et al. “Two new p73 splice variants, gamma and delta, with different transcriptional activity.” J Exp Med. 188(9):1763-8, 1998.
He Y, et al. “Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity.” Mol Endocrinol. 13(4):537-45, 1999.
Keyt Ba, et al. “The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency.” J Biol Chem. 271(13):7788-95, 1996.

Affiliated with

Also associated with

Rating

VEGF isoforms and their use as anti-angiogenic,... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with VEGF isoforms and their use as anti-angiogenic,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and VEGF isoforms and their use as anti-angiogenic,... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4200250